1. Home
  2. RCUS vs PTY Comparison

RCUS vs PTY Comparison

Compare RCUS & PTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$22.22

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Pimco Corporate & Income Opportunity Fund

PTY

Pimco Corporate & Income Opportunity Fund

HOLD

Current Price

$12.45

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCUS
PTY
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.5B
IPO Year
2018
2002

Fundamental Metrics

Financial Performance
Metric
RCUS
PTY
Price
$22.22
$12.45
Analyst Decision
Buy
Analyst Count
10
0
Target Price
$29.20
N/A
AVG Volume (30 Days)
1.1M
1.3M
Earning Date
05-28-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$247,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$57.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.79
$11.70
52 Week High
$26.40
$14.69

Technical Indicators

Market Signals
Indicator
RCUS
PTY
Relative Strength Index (RSI) 54.67 15.75
Support Level $20.35 N/A
Resistance Level $24.16 $13.17
Average True Range (ATR) 1.28 0.12
MACD 0.38 -0.05
Stochastic Oscillator 57.99 13.89

Price Performance

Historical Comparison
RCUS
PTY

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About PTY Pimco Corporate & Income Opportunity Fund

PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.

Share on Social Networks: